There is one clinical trial.
The investigators will follow a single prospective cohort of 50 Health Care Workers in the Hospital Italiano de Buenos Aires (Argentina) from May 15th to August 31st 2020 using antibody testing for SARS-CoV-2 IgM and IgG at baseline and every 2 weeks in order to assess the incidence of COVID-19, the prevalence of anti-SARS-CoV-2 antibodies (IgM and IgG) and incidence of reinfection or reactivations of previous COVID-19 using viral gene sequencing in this cohort.
Description: Patients that has a positive result for IgM or IgG at baseline first testMeasure: Prevalence of anti SARS-CoV-2 antibodies (IgM and IgG) in health personnel Time: Baseline at study inclussion
Description: Patients that has a positive result for IgM or IgG or PCR during follow upMeasure: COVID-19 incidence through serology-based screening and/or compatible symptoms in health personnel previously known to be unexposed to the virus Time: During 3 months follow up
Description: Patients with confirmed previous SARS Cov 2 antibodies that reactivate symptomons or new increase in antibodies title during follow upMeasure: Incidence of reactivation/reinfection for COVID-19 in health personnel with a positive serology for SARS-CoV-2 Time: During 3 months follow up
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports